Helma Pinchemel Cotrim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Helma Pinchemel Cotrim has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Paulo Adriano Schwingel
Programa de Pós-Graduação em Reabilitação e Desempenho Funcional (PPGRDF), Universidade de Pernambuco (UPE), Petrolina 56328-900, PE, Brazil
5 shared publications Gerson Bragagnoli
Faculdade de Medicina, Universidade Federal da Bahia (UFBA), Salvador, BA, Brasil
3 shared publicationsAndré Vinicius A. Florentino
Medical School, Universidade Federal de Campina Grande (UFCG), Campina Grande, PB, Brazil
2 shared publicationsCibelle P.V. Barreto
Medical School, Universidade Federal de Campina Grande (UFCG), Campina Grande, PB, Brazil
2 shared publicationsCláudio C. Zoppi
Departmento de Anatomia, Biologia Celular e Fisiologia e Biofísica, Instituto de Biologia, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
2 shared publicationsConsuelo P. Vilar
Postgraduate Program in Medicine and Health, Faculdade de Medicina da Bahia FMB, Universidade Federal da Bahia UFBA, Salvador, BA, Brazil
2 shared publications
Latest Publications
- Open Access
- 2 June 2023
- Published by Elsevier in Annals of Hepatology
- Vol. 28 (5) , 101122
Nonalcoholic fatty liver disease: A risk factor for chronic kidney disease
- 2 June 2023
- Published by Elsevier in Annals of Hepatology
- Vol. 28 (5) , 101122
Open AccessNonalcoholic fatty liver disease: A risk factor for chronic kidney disease
- 19 September 2015
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 50 (11) , 1490-1498
Recreational Anabolic-Androgenic Steroid Use Associated With Liver Injuries Among Brazilian Young Men
Background: The recreational use of anabolic-androgenic steroids (AAS) has reached alarming levels among healthy people. However, several complications have been related to consumption of these drugs, including liver disorders. Objective: To evaluate the prevalence of liver injuries in young Brazilian recreational AAS users. Methods: Between February/2007 and May/2012 asymptomatic bodybuilders who were ≥18 years old and reported AAS use for ≥6 months were enrolled. All had clinical evaluations, abdominal ultrasound (AUS), and blood tests. Results: 182 individuals were included in the study. The median age (interquartile range) was 26.0 years (22.0–30.0) and all were male. Elevated liver enzyme levels were observed in 38.5% (n = 70) of AAS users, and creatine phosphokinase was normal in 27.1% (n = 19) of them. Hepatic steatosis was observed by AUS in 12.1% of the sample. One individual had focal nodular hyperplasia and another had hepatocellular adenoma. One case each of hepatitis B and C virus infection was found. A diagnosis of toxic liver injury was suggested in 23 (12.6%) AAS users without a history of alcohol or other medications/drugs consumption, or evidence of other liver diseases. Conclusions/Importance: Young Brazilian recreational AAS users presented a wide spectrum of liver injuries that included hepatotoxicity, fatty liver, and liver neoplasm. They also presented risk factors for liver diseases such as alcohol consumption and hepatitis B and C virus infection. The results suggest that the risk of AAS use for the liver may be greater than the esthetic benefits, and demonstrate the importance of screening AAS users for liver injuries.
- 19 September 2015
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 50 (11) , 1490-1498
Recreational Anabolic-Androgenic Steroid Use Associated With Liver Injuries Among Brazilian Young Men
Background: The recreational use of anabolic-androgenic steroids (AAS) has reached alarming levels among healthy people. However, several complications have been related to consumption of these drugs, including liver disorders. Objective: To evaluate the prevalence of liver injuries in young Brazilian recreational AAS users. Methods: Between February/2007 and May/2012 asymptomatic bodybuilders who were ≥18 years old and reported AAS use for ≥6 months were enrolled. All had clinical evaluations, abdominal ultrasound (AUS), and blood tests. Results: 182 individuals were included in the study. The median age (interquartile range) was 26.0 years (22.0–30.0) and all were male. Elevated liver enzyme levels were observed in 38.5% (n = 70) of AAS users, and creatine phosphokinase was normal in 27.1% (n = 19) of them. Hepatic steatosis was observed by AUS in 12.1% of the sample. One individual had focal nodular hyperplasia and another had hepatocellular adenoma. One case each of hepatitis B and C virus infection was found. A diagnosis of toxic liver injury was suggested in 23 (12.6%) AAS users without a history of alcohol or other medications/drugs consumption, or evidence of other liver diseases. Conclusions/Importance: Young Brazilian recreational AAS users presented a wide spectrum of liver injuries that included hepatotoxicity, fatty liver, and liver neoplasm. They also presented risk factors for liver diseases such as alcohol consumption and hepatitis B and C virus infection. The results suggest that the risk of AAS use for the liver may be greater than the esthetic benefits, and demonstrate the importance of screening AAS users for liver injuries.
- Open Access
- 1 June 2015
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 52 (2) , 111-116
NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CORONARY DISEASE FROM A BRAZIL NORTHEAST AREA
Key words: Fatty liver; Coronary artery disease; Cardiovascular diseases; Coronary angiography
- 1 June 2015
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 52 (2) , 111-116
Open AccessNONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CORONARY DISEASE FROM A BRAZIL NORTHEAST AREA
Key words: Fatty liver; Coronary artery disease; Cardiovascular diseases; Coronary angiography
- Open Access
- 16 May 2013
- Published by Elsevier in Revista da Associação Médica Brasileira
- Vol. 59 (3) , 290-297
Association between nonalcoholic fatty liver disease and coronary artery disease
- 16 May 2013
- Published by Elsevier in Revista da Associação Médica Brasileira
- Vol. 59 (3) , 290-297
Open AccessAssociation between nonalcoholic fatty liver disease and coronary artery disease
- Open Access
- 1 January 2013
- Published by Elsevier in Revista da Associação Médica Brasileira (English Edition)
- Vol. 59 (3) , 290-297
Association between nonalcoholic fatty liver disease and coronary artery disease
- 1 January 2013
- Published by Elsevier in Revista da Associação Médica Brasileira (English Edition)
- Vol. 59 (3) , 290-297
Open AccessAssociation between nonalcoholic fatty liver disease and coronary artery disease
- 26 May 2011
- Published by Wiley in Liver International
- Vol. 31 (8) , 1240-1241
Increased liver steatosis in anabolic‐androgenic steroid users: more evidence towards toxicant‐associated fatty liver disease development
- 26 May 2011
- Published by Wiley in Liver International
- Vol. 31 (8) , 1240-1241
Increased liver steatosis in anabolic‐androgenic steroid users: more evidence towards toxicant‐associated fatty liver disease development
- Open Access
- 1 January 2011
- Published by Elsevier in Annals of Hepatology
- Vol. 10 (1) , 33-37
Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile
- 1 January 2011
- Published by Elsevier in Annals of Hepatology
- Vol. 10 (1) , 33-37
Open AccessNonalcoholic fatty liver disease in Brazil. Clinical and histological profile
- 11 October 2010
- Published by Wiley in Liver International
- Vol. 31 (3) , 348-353
Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease
Industrial toxin and drugs have been associated with non-alcoholic fatty liver disease (NAFLD); in these cases, the disease has been termed toxicant-associated steatohepatitis (TASH). This study hypothesizes that the use of anabolic-androgenic steroids (AAS) could also be a risk factor to TASH or better toxicant-associated fatty liver disease (TAFLD) development. Case-control study including 180 non-competitive recreational male bodybuilders from August/2007 to March/2009. Ninety-five had a history of intramuscular AAS use (cases; G1) and 85 were non-users (controls; G2). They underwent a clinical evaluation and abdominal ultrasound, and their blood levels of aminotransferases, creatine phosphokinase (CPK), lipids, glucose and insulin were measured. TAFLD criteria: history of AAS use >2 years; presence of hepatic steatosis on ultrasound and/or aminotransferase alterations with normal CPK levels; exclusion of ethanol intake ≥20 g/day or use of other drugs; and exclusion of obesity, dyslipidaemia, diabetes and other liver diseases. Homeostasis model assessment for insulin resistance ≥3 was considered insulin resistant. Independent t-test, odds ratio (OR) and 95% confidence intervals (95% CI) were calculated. All cases were asymptomatic. Clinical and laboratorial data were similar in G1 and G2 (P>0.05). TAFLD criteria were observed in 12.6% of the G1 cases and 2.4% of controls had criteria compliant with non-alcoholic fatty liver related to metabolic conditions. OR was 6.0 (95% CI: 1.3-27.6). These results suggest that AAS could be a possible new risk factor for TAFLD. In this type of fatty liver disease, the individuals had a low body fat mass and they did not present insulin resistance.
- 11 October 2010
- Published by Wiley in Liver International
- Vol. 31 (3) , 348-353
Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease
Industrial toxin and drugs have been associated with non-alcoholic fatty liver disease (NAFLD); in these cases, the disease has been termed toxicant-associated steatohepatitis (TASH). This study hypothesizes that the use of anabolic-androgenic steroids (AAS) could also be a risk factor to TASH or better toxicant-associated fatty liver disease (TAFLD) development. Case-control study including 180 non-competitive recreational male bodybuilders from August/2007 to March/2009. Ninety-five had a history of intramuscular AAS use (cases; G1) and 85 were non-users (controls; G2). They underwent a clinical evaluation and abdominal ultrasound, and their blood levels of aminotransferases, creatine phosphokinase (CPK), lipids, glucose and insulin were measured. TAFLD criteria: history of AAS use >2 years; presence of hepatic steatosis on ultrasound and/or aminotransferase alterations with normal CPK levels; exclusion of ethanol intake ≥20 g/day or use of other drugs; and exclusion of obesity, dyslipidaemia, diabetes and other liver diseases. Homeostasis model assessment for insulin resistance ≥3 was considered insulin resistant. Independent t-test, odds ratio (OR) and 95% confidence intervals (95% CI) were calculated. All cases were asymptomatic. Clinical and laboratorial data were similar in G1 and G2 (P>0.05). TAFLD criteria were observed in 12.6% of the G1 cases and 2.4% of controls had criteria compliant with non-alcoholic fatty liver related to metabolic conditions. OR was 6.0 (95% CI: 1.3-27.6). These results suggest that AAS could be a possible new risk factor for TAFLD. In this type of fatty liver disease, the individuals had a low body fat mass and they did not present insulin resistance.
- 1 September 2009
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 21 (9) , 969-972
Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients
Objectives The effect of light-to-moderate alcohol consumption (LMAC) in nonalcoholic fatty liver disease (NAFLD) remains a controversial subject. The aim of this study was to evaluate the relationship between LMAC and the severity of NAFLD in morbidly obese patients. Methods We studied 132 patients undergoing liver biopsy during bariatric surgery. The patients were divided into three groups: G1: alcohol intake greater than 20 g/day and less than 40 g/day; G2: alcohol intake less than 20 g/day; G3: no alcohol intake. Insulin resistance was defined by the Homeostasis Model Assessment (>3). NAFLD was classified according to the Matteoni types: type I: steatosis alone; type II: steatosis with inflammation; types III–IV: steatosis with ballooning and/or fibrosis. Results The mean age was 37.3±11 years. Sixty-three percent were females and body mass index was 43.9±5.6 kg/m2. G1, G2, and G3 included 19, 56, and 57 patients, respectively. Histological diagnoses classified by levels of alcohol were: G1: 10.5% normal liver, 89.5% type III or IV; G2: 10.7% normal liver, 1.8% type I or II, and 87.5% grade III or IV; G3: 10.5% normal liver, 3.5% type I or II, and 86% type III or IV (one had cirrhosis). The presence of IR was similar in moderate and no alcohol consumption (81.3 and 78.7%) but significantly less in the light consumption group (54%, P<0.05). Conclusion The results suggest that LMAC may have a protection effect against IR in severely obese patients. However, it had no impact on the severity of activity and stage of liver disease.
- 1 September 2009
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 21 (9) , 969-972
Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients
Objectives The effect of light-to-moderate alcohol consumption (LMAC) in nonalcoholic fatty liver disease (NAFLD) remains a controversial subject. The aim of this study was to evaluate the relationship between LMAC and the severity of NAFLD in morbidly obese patients. Methods We studied 132 patients undergoing liver biopsy during bariatric surgery. The patients were divided into three groups: G1: alcohol intake greater than 20 g/day and less than 40 g/day; G2: alcohol intake less than 20 g/day; G3: no alcohol intake. Insulin resistance was defined by the Homeostasis Model Assessment (>3). NAFLD was classified according to the Matteoni types: type I: steatosis alone; type II: steatosis with inflammation; types III–IV: steatosis with ballooning and/or fibrosis. Results The mean age was 37.3±11 years. Sixty-three percent were females and body mass index was 43.9±5.6 kg/m2. G1, G2, and G3 included 19, 56, and 57 patients, respectively. Histological diagnoses classified by levels of alcohol were: G1: 10.5% normal liver, 89.5% type III or IV; G2: 10.7% normal liver, 1.8% type I or II, and 87.5% grade III or IV; G3: 10.5% normal liver, 3.5% type I or II, and 86% type III or IV (one had cirrhosis). The presence of IR was similar in moderate and no alcohol consumption (81.3 and 78.7%) but significantly less in the light consumption group (54%, P<0.05). Conclusion The results suggest that LMAC may have a protection effect against IR in severely obese patients. However, it had no impact on the severity of activity and stage of liver disease.
- 1 December 2007
- Vol. 37 (4) , 224-30
[Nonalcoholic fatty liver disease: clinical and histological characteristics in obese who underwent bariatric surgery].
Obesity is an important risk factor of Nonalcoholic Fatty Liver Disease (NAFLD) and it has been considered a predictor of severity of this condition. However, in severe obese patients the spectrum of NAFLD is in discussion. To describe the clinical and histological characteristics of NAFLD in obese patients submitted to bariatric surgery. The study included 141 severe obese (BMI > or = 35kg/m2) who underwent bariatric surgery from October 2004 to May 2005 had clinical and histological diagnosis of NAFLD. alcoholic intake more than 140 g/week, positive markers for other liver diseases. All patients were submitted to hepatic biopsy, as first procedure during the surgery. The mean age of the patients was of 37.3 +/- 11.1 years and 76.4% were female. BMI was greater than 40 kg/m2 in 77.7% of the cases. The frequency of metabolic syndrome was 51.9% (104). Elevated aminotransferases and hepatic steatosis on ultrasound were present in 29.5% (105) and 59.0% (105) respectively. Normal liver biopsy or unspecfic findings were found in 11.3% of the cases and NAFLD in 88.7%: isolated steatosis in 2.8%, steatohepatitis (NASH) in 85.1% (NASH and fibrosis in 76.6%) and cirrhosis in 0.7%. NAFLD in severe obese patients, in general, was asymptomatic and presented normal enzymes, liver function and ultrasound. However, it has a large histological spectrum and cases of steatohepatitis with fibrosis were more frequent. These results suggest that liver biopsy may be considered during the bariatric surgery to better diagnosis and prognosis of severe obese patients.
- 1 December 2007
- Vol. 37 (4) , 224-30
[Nonalcoholic fatty liver disease: clinical and histological characteristics in obese who underwent bariatric surgery].
Obesity is an important risk factor of Nonalcoholic Fatty Liver Disease (NAFLD) and it has been considered a predictor of severity of this condition. However, in severe obese patients the spectrum of NAFLD is in discussion. To describe the clinical and histological characteristics of NAFLD in obese patients submitted to bariatric surgery. The study included 141 severe obese (BMI > or = 35kg/m2) who underwent bariatric surgery from October 2004 to May 2005 had clinical and histological diagnosis of NAFLD. alcoholic intake more than 140 g/week, positive markers for other liver diseases. All patients were submitted to hepatic biopsy, as first procedure during the surgery. The mean age of the patients was of 37.3 +/- 11.1 years and 76.4% were female. BMI was greater than 40 kg/m2 in 77.7% of the cases. The frequency of metabolic syndrome was 51.9% (104). Elevated aminotransferases and hepatic steatosis on ultrasound were present in 29.5% (105) and 59.0% (105) respectively. Normal liver biopsy or unspecfic findings were found in 11.3% of the cases and NAFLD in 88.7%: isolated steatosis in 2.8%, steatohepatitis (NASH) in 85.1% (NASH and fibrosis in 76.6%) and cirrhosis in 0.7%. NAFLD in severe obese patients, in general, was asymptomatic and presented normal enzymes, liver function and ultrasound. However, it has a large histological spectrum and cases of steatohepatitis with fibrosis were more frequent. These results suggest that liver biopsy may be considered during the bariatric surgery to better diagnosis and prognosis of severe obese patients.